Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Rating) – Zacks Small Cap issued their Q2 2023 earnings estimates for shares of Tenax Therapeutics in a research report issued to clients and investors on Monday, May 22nd. Zacks Small Cap analyst J. Vandermosten forecasts that the specialty pharmaceutical company will earn ($0.13) per share for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Tenax Therapeutics’ Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.12) EPS, FY2023 earnings at ($0.51) EPS, FY2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.17) EPS.
Several other analysts also recently commented on TENX. Roth Capital reaffirmed a “buy” rating on shares of Tenax Therapeutics in a research report on Tuesday, March 7th. StockNews.com upgraded Tenax Therapeutics to a “sell” rating in a report on Wednesday, March 22nd. Finally, Roth Mkm initiated coverage on Tenax Therapeutics in a report on Tuesday, March 7th. They issued a “buy” rating and a $6.00 target price on the stock.
Tenax Therapeutics Price Performance
Hedge Funds Weigh In On Tenax Therapeutics
A hedge fund recently bought a new stake in Tenax Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Rating) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 84,361 shares of the specialty pharmaceutical company’s stock, valued at approximately $39,000. Virtu Financial LLC owned approximately 0.38% of Tenax Therapeutics at the end of the most recent quarter. 34.08% of the stock is currently owned by institutional investors and hedge funds.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.
- Get a free copy of the StockNews.com research report on Tenax Therapeutics (TENX)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.